866-997-4948(US-Canada Toll Free)

Global Respiratory Drugs Market 2016-2020

Published By :

Technavio

Published Date : May 2016

Category :

Metabolic Disorders

No. of Pages : 120 Pages

About Respiratory Ailments

Asthma, COPD, allergic rhinitis, pulmonary hypertension, cystic fibrosis, and IPF are some of the major respiratory diseases. Among these, asthma and COPD are the most prevalent worldwide. Environmental pollution, changing lifestyles, and hereditary factors are some of the common causes of respiratory diseases. Intranasal corticosteroids, antihistamines, immunosuppressants, bronchodilators, and leukotriene antagonists are the respiratory medicines that are commonly used for the treatment of mild-to-moderate respiratory diseases. However, the choice of drug depends on the type and severity of the disease.

Technavios analysts forecast the global respiratory drugs market to grow at a CAGR of 6.48% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global respiratory drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription and over-the-counter (OTC) drugs used to treat respiratory diseases.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Respiratory Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
AstraZeneca
Boehringer Ingelheim
F.Hoffman La-Roche
GlaxoSmithKline
Merck
Novartis

Other prominent vendors
Abbott
Actavis
Afferent Pharmaceuticals
Alere
Almirall
Amgen
AptarGroup
Astellas
Aurobindo
Axis Shield
Baxter
Bayer
Biogen
Biotest
Bristol-Myers Squibb
Chiesi Farmaceutici
Cipla
Cytos
Dainippon Sumitomo
Dr. Reddy's Laboratories
FibroGen
Gilead Sciences
Glenmark
GNI Group Ltd
Horizon Pharma
ImmuneWorks
MediciNova
MedImmune
Mylan
Ono Pharmaceutical
Orchid Chemicals and Pharmaceuticals
Perrigo
Pfizer
Promedior
Prometheus
ProMetic Life Sciences
Ranbaxy
Rottapharm Madaus
Sanofi
Shionogi
Siemens Healthcare Diagnostics
Skyepharma
Sosei
Sunovion
Takeda Pharmaceutical
Teva
Theravance
United Therapeutics
Vectura
Vertex
Zai Lab

Market driver
Rise in prevalence of respiratory diseases
For a full, detailed list, view our report

Market challenge
Unknown etiology of asthma and idiopathic pulmonary fibrosis
For a full, detailed list, view our report

Market trend
Use of biologics
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.

PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Overview: Respiratory diseases
Asthma
COPD
Allergic rhinitis
Pulmonary hypertension
Cystic fibrosis
IPF
US FDA-approved respiratory drugs
PART 06: Pipeline analysis
Information on some pipeline candidates
PART 07: Market landscape
Five forces analysis
PART 08: Market segmentation by class of drugs
Bronchodilators
Leukotriene antagonists
Mast cell stabilizers
Immunosuppressants
Combination of LABA/ICS
Tyrosine kinase inhibitors
Antifibrotic agents
Antihistamines
Endothelin (ET) receptor antagonist
Prostacyclin analogs
Phosphodiesterase inhibitors
Soluble guanylate cyclase (sGC) stimulators
PART 09: Market segmentation by disease
Global asthma drugs market
Global COPD drugs market
Global allergic rhinitis drugs market
Global pulmonary hypertension drugs market
Global cystic fibrosis drugs market
Global IPF drugs market
PART 10: Geographical segmentation
Global respiratory drugs market by geography 2015-2020
Respiratory drugs market in Americas
Respiratory drugs market in EMEA
Respiratory drugs market in APAC
PART 11: Market drivers
Promising late-stage pipeline molecules
Rise in prevalence of respiratory diseases
Increase in older adult population
High usage of tobacco
Increase in environmental pollution
PART 12: Impact of drivers
PART 13: Market challenges
Multiple patent expiries
Unknown etiology of asthma and IPF
Low diagnosis rates
Adverse effects of drugs
Increased preference for CAM
PART 14: Impact of drivers and challenges
PART 15: Market trends
Increasing awareness about respiratory diseases
Patient assistance programs
Usage of biologics
Self-medication using OTC products
Strategic alliances
PART 16: Vendor landscape
Competitive scenario
Market share analysis 2015
AstraZeneca
Boehringer Ingelheim
F. Hoffmann-La Roche
GlaxoSmithKline
Merck
Novartis
Other prominent vendors
PART 17: Appendix
List of abbreviations
PART 18: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Objectives of asthma management
Exhibit 03: COPD: Prevalence in six EU countries
Exhibit 04: Management of COPD
Exhibit 05: Prevalence rate of allergic rhinitis in China
Exhibit 06: Summary of pharmacologic treatments for allergic rhinitis
Exhibit 07: Non-pharmacological therapies for allergic rhinitis
Exhibit 08: Prevalence of cystic fibrosis by country 2014
Exhibit 09: Treatment options for IPF
Exhibit 10: Drugs approved by US FDA for respiratory diseases 2000-2015
Exhibit 11: Pipeline portfolio of major drug candidates for respiratory diseases
Exhibit 12: Global respiratory drugs market 2015-2020 ($ billions)
Exhibit 13: Global respiratory drugs market by diseases 2015
Exhibit 14: Five forces analysis
Exhibit 15: Global asthma drugs market 2015-2020 ($ billions)
Exhibit 16: Key drivers and challenges of global asthma drugs market
Exhibit 17: Global asthma drugs market by class of drugs 2015
Exhibit 18: Global COPD drugs market 2015-2020 ($ billions)
Exhibit 19: Key drivers and challenges of global COPD drugs market
Exhibit 20: Global COPD drugs market by class of drugs 2015
Exhibit 21: Global allergic rhinitis drugs market 2015-2020 ($ billions)
Exhibit 22: Key drivers and challenges of global allergic rhinitis drugs market
Exhibit 23: Global allergic rhinitis drugs market by class of drugs 2015
Exhibit 24: Global pulmonary hypertension drugs market 2015-2020 ($ billions)
Exhibit 25: Key drivers and challenges for global pulmonary hypertension drugs market
Exhibit 26: Global pulmonary hypertension drugs market by class of drugs 2015
Exhibit 27: Global cystic fibrosis drugs market 2015-2020 ($ billions)
Exhibit 28: Key drivers and challenges for global cystic fibrosis drugs market
Exhibit 29: Global cystic fibrosis drugs market by type of molecule 2015
Exhibit 30: Global IPF market 2015-2020 ($ billions)
Exhibit 31: Key drivers and challenges for global IPF drugs market
Exhibit 32: Global respiratory drugs market: YoY revenue and growth based on respiratory diseases 2015-2020
Exhibit 33: Global respiratory drugs market by geography 2015
Exhibit 34: Global respiratory drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 35: Respiratory drugs market in Americas 2015-2020 ($ billions)
Exhibit 36: Respiratory drugs market in EMEA 2015-2020 ($ billions)
Exhibit 37: Respiratory drugs market in APAC 2015-2020 ($ billions)
Exhibit 38: Global respiratory drugs market; YoY revenue and growth based on geography 2015-2020
Exhibit 39: Impact of drivers
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Drugs that converted from Rx to OTC
Exhibit 42: Global respiratory drugs market share analysis 2015
Exhibit 43: Top selling respiratory drugs based on their revenue in 2014
Exhibit 44: AstraZeneca: Percentage share of products sales by therapy area 2014
Exhibit 45: AstraZeneca: YoY growth and revenue of Symbicort 2012-2014 ($ billions)
Exhibit 46: AstraZeneca: YoY growth and revenue of Pulmicort 2012-2014 ($ billions)
Exhibit 47: AstraZeneca: Key takeaways
Exhibit 48: Boehringer Ingelheim: YoY growth and revenue of Spiriva 2012-2014 ($ billions)
Exhibit 49: Boehringer Ingelheim: YoY growth and revenue of Combivent 2012-2014 ($ millions)
Exhibit 50: Boehringer Ingelheim: Key takeaways
Exhibit 51: F. Hoffmann-La Roche: YoY growth and revenue of Xolair in the US 2012-2014 ($ millions)
Exhibit 52: F. Hoffmann-La Roche: YoY growth and revenue of Pulmozyme 2012-2014 ($ millions)
Exhibit 53: F. Hoffmann-La Roche: Key takeaways
Exhibit 54: GlaxoSmithKline: Percentage share of products sales by therapy area 2014
Exhibit 55: GlaxoSmithKline: YoY growth and revenue of Seretide/Advair 2012-2014 ($ billions)
Exhibit 56: GlaxoSmithKline: YoY growth and revenue of Flixotide/Flovent 2012-2014 ($ billions)
Exhibit 57: GlaxoSmithKline: YoY growth and revenue of Ventolin 2012-2014 ($ billions)
Exhibit 58: GlaxoSmithKline: YoY growth and revenue of Avamys/Veramyst 2012-2014 ($ millions)
Exhibit 59: GlaxoSmithKline: YoY revenue of Avamys/Veramyst 2013 and 2014 ($ millions)
Exhibit 60: GlaxoSmithKline: Key takeaways
Exhibit 61: Merck: YoY growth and revenue of Nasonex 2012-2014 ($ billions)1
Exhibit 62: Merck: YoY growth and revenue of Singulair 2012-2014 ($ billions)2
Exhibit 63: Merck: YoY growth and revenue of Clarinex 2012-2014 ($ millions)2
Exhibit 64: Merck: Key takeaways4
Exhibit 65: Novartis: YoY growth and revenue of Xolair (outside the US) 2012-2014 ($ millions)6
Exhibit 66: Novartis: YoY growth and revenue of TOBI 2012-2014 ($ millions)6
Exhibit 67: Novartis: YoY growth and revenue of Onbrez Breezhaler 2012-2014 ($ millions)7
Exhibit 68: Novartis: YoY growth and revenue of Seebri Breezhaler 2012-2014 ($ millions)7
Exhibit 69: Novartis: YoY revenue of Ultibro Breezhaler 2013 and 2014 ($ millions)8
Exhibit 70: Novartis: YoY growth and revenue of Foradil Aerolizer sold outside the US 2012-2014 ($ millions)8
Exhibit 71: Novartis: Key takeaways9

List of Table

NA

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *